CN111471651A - 一种人脂肪干细胞无血清培养基及其制备方法 - Google Patents
一种人脂肪干细胞无血清培养基及其制备方法 Download PDFInfo
- Publication number
- CN111471651A CN111471651A CN202010330554.3A CN202010330554A CN111471651A CN 111471651 A CN111471651 A CN 111471651A CN 202010330554 A CN202010330554 A CN 202010330554A CN 111471651 A CN111471651 A CN 111471651A
- Authority
- CN
- China
- Prior art keywords
- serum
- stem cells
- culture medium
- derived stem
- dmem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 51
- 239000012679 serum free medium Substances 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title description 13
- 239000001963 growth medium Substances 0.000 claims abstract description 39
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims abstract description 37
- 239000000654 additive Substances 0.000 claims abstract description 24
- 230000000996 additive effect Effects 0.000 claims abstract description 24
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 21
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 21
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims abstract description 20
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims abstract description 20
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims abstract description 18
- 239000004017 serum-free culture medium Substances 0.000 claims abstract description 17
- 229930183010 Amphotericin Natural products 0.000 claims abstract description 12
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940009444 amphotericin Drugs 0.000 claims abstract description 12
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims abstract description 12
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims abstract description 11
- 229930182566 Gentamicin Natural products 0.000 claims abstract description 11
- 229960002518 gentamicin Drugs 0.000 claims abstract description 11
- 108010067306 Fibronectins Proteins 0.000 claims abstract description 9
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960002897 heparin Drugs 0.000 claims abstract description 6
- 229920000669 heparin Polymers 0.000 claims abstract description 6
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims abstract 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims abstract 5
- 102000016359 Fibronectins Human genes 0.000 claims abstract 5
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims abstract 5
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims abstract 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims abstract 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract 4
- 102000013275 Somatomedins Human genes 0.000 claims abstract 4
- 229960004308 acetylcysteine Drugs 0.000 claims abstract 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims abstract 4
- 101800003838 Epidermal growth factor Proteins 0.000 claims abstract 3
- 229940116977 epidermal growth factor Drugs 0.000 claims abstract 3
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 claims abstract 2
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 claims abstract 2
- -1 B27 Proteins 0.000 claims description 15
- 239000002609 medium Substances 0.000 claims description 8
- 239000007640 basal medium Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims 2
- 101710148262 3-hexulose-6-phosphate synthase Proteins 0.000 claims 1
- 102100028902 Hermansky-Pudlak syndrome 1 protein Human genes 0.000 claims 1
- 101710180013 Probable hexaprenyl pyrophosphate synthase, mitochondrial Proteins 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 abstract description 8
- 241000700605 Viruses Species 0.000 abstract description 3
- 239000002158 endotoxin Substances 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 15
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 7
- 108010024636 Glutathione Proteins 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 102100037362 Fibronectin Human genes 0.000 description 4
- 102000004338 Transferrin Human genes 0.000 description 4
- 108090000901 Transferrin Proteins 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000012581 transferrin Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007822 cytometric assay Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides, bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
- C12N2501/91—Heparin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种人脂肪干细胞无血清培养基,包括DMEM/F12基础培养基和添加成分,其中添加成分为:人血清白蛋白、B27添加剂或类似物、碱性成纤维生长因子、酸性成纤维生长因子、血小板源生长因子、表皮生长因子、***、肝素、纤粘连蛋白、抗坏血酸磷酸酯镁盐、N‑乙酰半胱氨酸、庆大霉素和两性霉素。本发明人脂肪干细胞无血清培养基,不含任何血清成分,且成分明确,避免了动物血清内潜在动物源性内毒素或病毒将对人体健康构成极大地风险,所含组分均来自重组蛋白或化学合成,不会引起人体免疫排斥,解决了应用的安全性问题。
Description
技术领域
本发明属于细胞培养技术领域,具体地说,涉及一种人脂肪干细胞无血清培养基及其制备方法。
背景技术
目前常用的人脂肪干细胞(hADSCs)培养是利用饲养层细胞与采用含10%胎牛血清的培养基进行培养。这种培养干细胞方法的缺点是方法复杂,提取干细胞数量少,纯度不高,继代增殖缓慢,更大问题是使用饲养层细胞和动物血清容易导致干细胞污染,特别是动物血清内潜在动物源性内毒素或病毒将对人体健康构成极大地风险,这样培养出的干细胞不适于直接应用于临床。因此,开发一种合适的有效的培养基变的迫在眉睫。
发明内容
本发明的目的是提供一种人脂肪干细胞无血清培养基,其不含动物血清成分,可以完全实现无血清培养人脂肪干细胞;采用本发明无血清培养基培养人脂肪干细胞,可在体外获得高数量、高纯度并且安全优质的人脂肪干细胞,同时可提高细胞存活率,维持干细胞的特性。
本发明的另一个目的是提供一种人脂肪干细胞无血清培养基的制备方法。
为了解决上述技术问题,本发明公开的第一个技术方案是,一种人脂肪干细胞无血清培养基,包括DMEM/F12基础培养基和添加成分,其中添加成分为:HSA、B27、bFGF、aFGF、PDGF、EGF、HPS、FN、Vc-Mg、NAC、 Gent-AMP。
进一步地,DMEM/F12基础培养基中DMEM培养基与F12培养基的质量比为1:2。
优选地,添加成分在DMEM/F12基础培养基中的含量为:
B27添加剂或类似物:0.5-2×;
HSA:2-50mg/ml;
IGF:1-100ng/ml
bFGF:2-20ng/ml;
aFGF:2-20ng/ml;
PDGF:2-20ng/ml;
EGF:2-20ng/ml;
Vc-Mg:10-100μg/ml
NAC:1-10mg/ml;
HPS:1-10mg/ml;
FN:10-100ug/ml;
庆大霉素:1-20μg/ml;
两性霉素:1-10μg/ml;
更优选地,添加成分在DMEM/F12基础培养基中的含量为:
HSA:5-25mg/ml;
IGF:2-50ng/ml
bFGF:4-10ng/ml;
aFGF:4-10ng/ml;
PDGF:4-10ng/ml;
EGF:4-10ng/ml;
Vc-Mg:20-50μg/ml
NAC:2-10mg/ml;
HPS:2-10mg/ml;
FN:20-50ug/ml;
庆大霉素:1-20μg/ml;
两性霉素:2-10μg/ml;
最优选地,添加成分在DMEM/F12基础培养基中的含量为:
HSA:10mg/ml;
IGF:10ng/ml
bFGF:5ng/ml;
aFGF:5ng/ml;
PDGF:5ng/ml;
EGF:5ng/ml;
Vc-Mg:25μg/ml
NAC:5mg/ml;
HPS:5mg/ml;
FN:25ug/ml;
庆大霉素:10μg/ml;
两性霉素:5μg/ml;
本发明公开的第二个技术方案是,一种人脂肪干细胞无血清培养基的制备方法,在无菌环境下下,取DMEM/F12基础培养基,依次加入HSA、B27、 bFGF、aFGF、PDGF、EGF、HPS、FN、Vc-Mg、NAC、Gent-AMP混合均匀,得到人脂肪干细胞无血清培养基。
本发明公开的第三个技术方案是,人脂肪干细胞无血清培养基在培养人脂肪干细胞中的应用。
与现有技术相比,本发明可以获得包括以下技术效果:
1)本发明人脂肪干细胞无血清培养基,不含任何血清成分,且成分明确,避免了动物血清内潜在动物源性内毒素或病毒将对人体健康构成极大地风险,所含组分均来自重组蛋白或化学合成,不会引起人体免疫排斥,解决了应用的安全性问题。
2)采用本发明无血清培养基培养人脂肪干细胞,细胞增殖速率高,细胞能够保持较高的完整性和活性,适用于大规模的人脂肪干细胞培养,成本低廉且方便配制。
3)采用本发明无血清培养基培养人脂肪干细胞,可在体外获得高数量、高纯度并且安全优质的人脂肪干细胞,同时可提高细胞存活率,维持干细胞的特性。
附图说明
图1是脂肪干细胞在本发明无血清培养基培养下的增殖活性;
图2是脂肪干细胞的流式细胞表性检测。
具体实施方式
以下将配合实施例来详细说明本发明的实施方式,藉此对本发明如何应用技术手段来解决技术问题并达成技术功效的实现过程能充分理解并据以实施。
本发明公开了一种人脂肪干细胞无血清培养基,包括DMEM/F12基础培养基和添加成分,其中添加成分为:HSA、B27、bFGF、aFGF、PDGF、 EGF、HPS、FN、Vc-Mg、NAC、Gent-AMP。
DMEM/F12基础培养基中DMEM培养基与F12培养基的质量比为1:2。
添加成分在DMEM/F12基础培养基中的含量为:
B27添加剂(100×):0.25-2%;
HSA:2-50mg/ml;
IGF:1-100ng/ml
bFGF:2-20ng/ml;
aFGF:2-20ng/ml;
PDGF:2-20ng/ml;
EGF:2-20ng/ml;
Vc-Mg:10-100μg/ml
NAC:1-10mg/ml;
肝素(HPS):1-10mg/ml;
纤粘连蛋白:10-100ug/ml;
庆大霉素:1-20μg/ml;
两性霉素:1-10μg/ml;
本发明还公开了上述人脂肪干细胞无血清培养基的制备方法,在无菌环境下下,取DMEM/F12基础培养基,依次加入人血清白蛋白、B27、转铁蛋白、还原型谷胱甘肽、bFGF、aFGF、PDGF、EGF、Gent-AMP、Vc-Mg和 NAC,混合均匀,得到人脂肪干细胞无血清培养基。
本发明人脂肪干细胞无血清培养基中各组分的作用:
DMEM/F12基础培养基:DMEM培养基是一种含各种氨基酸和葡萄糖的培养基,F12培养基,成分复杂,含有多种微量元素,本发明采用DMEM/F12基础培养基,以利用F12含有较丰富的成份和DMEM含有较高浓度的营养成分的优点。
人血清白蛋白(HSA):能够运输维生素、脂肪酸类等营养物质,促进细胞新陈代谢以及保护细胞不受蛋白酶的损伤。
B27及类似物、是指B27添加剂及其同类产品,还包括B27添加剂的后续改进或替代产品。本方案B27添加剂等可以是由赛默飞世尔(Thermo Fisher)等公司出售的产品,也可以是其他公司出售或按已公开配方配制添加剂,这类产品多用于胚胎干细胞,多能干细胞,神经干细胞及神经元等的培养。本发明的实施例中,采用的是由赛默飞世尔公司出售的B27添加剂。
还原型谷胱甘肽:作为抗氧化剂,具有抑制细胞糖酵解作用,抑制细胞凋亡作用。
L-谷氨酰胺:作为培养细胞的能量来源、参与蛋白质的合成和核酸代谢。
重组碱性成纤维细胞生长因子bFGF、重组酸性性成纤维细胞生长因子 aFGF、血小板衍生因子PDGF和重组表皮生长因子EGF,是维持细胞体外生长增殖、***分化所必需的生物补充因子
Vc-Mg:维生素C为脂肪干细胞培养提供营养,参与细胞的蛋白质代谢、脂肪代谢、糖代谢等重要生命活动。
NAC:抗氧化剂
庆大霉素:广谱抗菌剂,保存时间长,在常温性质稳定;
两性霉素:真菌抗菌剂;
下面结合实施例对本发明作进一步的说明。
下述实施例中所涉及的仪器、试剂、材料等,若无特别说明,均为现有技术中已有的常规仪器、试剂、材料等,可通过正规商业途径获得。下述实施例中所涉及的实验方法,检测方法等,若无特别说明,均为现有技术中已有的常规实验方法,检测方法等。
实施例1制备人脂肪干细胞培养基
包括DMEM/F12基础培养基和添加成分,其中DMEM/F12基础培养基中DMEM培养基与F12培养基的质量比为1:2;
添加成分在DMEM/F12基础培养基中的含量为:
HSA:10mg/ml;
B27或类似物:1%
IGF:10ng/ml
bFGF:5ng/ml;
aFGF:5ng/ml;
PDGF:5ng/ml;
EGF:5ng/ml;
Vc-Mg:25μg/ml
NAC:5mg/ml;
肝素(HPS):5mg/ml;
纤粘连蛋白:25ug/ml;
庆大霉素:10μg/ml;
两性霉素:5μg/ml;
制备方法为:在无菌环境下下,取DMEM/F12基础培养基,依次加入人血清白蛋白、B27、转铁蛋白、还原型谷胱甘肽、bFGF、aFGF、PDGF、EGF、Gent-AMP、Vc-Mg和NAC,混合均匀,即得。
实施例2制备人脂肪干细胞培养基
包括DMEM/F12基础培养基和添加成分,其中DMEM/F12基础培养基中DMEM培养基与F12培养基的质量比为1:2;
添加成分在DMEM/F12基础培养基中的含量为:
HSA:50mg/ml;
B27或类似物:2%
IGF:20ng/ml
bFGF:10ng/ml;
aFGF:10ng/ml;
PDGF:10ng/ml;
EGF:10ng/ml;
Vc-Mg:50μg/ml
NAC:10mg/ml;
HPS:10mg/ml;
纤粘连蛋白:50ug/ml;
庆大霉素:10μg/ml;
两性霉素:5μg/ml;
制备方法为:在无菌环境下下,取DMEM/F12基础培养基,依次加入人血清白蛋白、B27、转铁蛋白、还原型谷胱甘肽、bFGF、aFGF、PDGF、 EGF、Gent-AMP、Vc-Mg和NAC,混合均匀,即得。
实施例3制备人脂肪干细胞培养基
包括DMEM/F12基础培养基和添加成分,其中DMEM/F12基础培养基中DMEM培养基与F12培养基的质量比为1:2;
添加成分在DMEM/F12基础培养基中的含量为:
HSA:5mg/ml;
B27或类似物:0.25%
IGF:5ng/ml
bFGF:2ng/ml;
aFGF:2ng/ml;
PDGF:5ng/ml;
EGF:5ng/ml;
Vc-Mg:10μg/ml
NAC:5mg/ml;
肝素(HPS):5mg/ml;
纤粘连蛋白:20ug/ml;
庆大霉素:10μg/ml;
两性霉素:5μg/ml;
制备方法为:在无菌环境下下,取DMEM/F12基础培养基,依次加入人血清白蛋白、B27、转铁蛋白、还原型谷胱甘肽、bFGF、aFGF、PDGF、 EGF、Gent-AMP、Vc-Mg和NAC,混合均匀,即得。
对比实验
将实施例2制备的无血清培养基置于T25细胞培养瓶中,将人脂肪干细胞以1.0×104cells/cm2接种,在温度37℃下培养,统计原代细胞的长出时间,每代的生长时间。
同时,以Lonza间充质干细胞无血清培养基(市售)为对照培养人脂肪干细胞。
结论:
原代细胞收获时间:通常的细胞培养基进行酶消化法分离细胞,7-9天可收获原代细胞,而本发明的无血清培养基爬出细胞时间缩短至6-7天,提高了效率。
细胞每代生长时间,经过连续10代监测,平均每代生长时间在2-3天,比Lonza无血清培养基培养时间缩短了一天,节约了培养时间,提高了工作效率。
连续传代次数:传统的MSC无血清培养基传代至6代以后,细胞生长变缓慢,本发明无血清培养基可连续传代至10代,细胞仍保持其分化潜能,而对照培养基传代至第9代后,细胞生长明显变缓,导致后期无法传代。
如图1所示,是脂肪干细胞在本发明无血清培养基和含10%血清培养基培养下的增殖活性曲线。由图1所示,实验表明本发明的培养基与含血清培养基无明显差异。
图2是脂肪干细胞的流式细胞表性检测。由图2所见,按本发明的培养方法培养脂肪干细胞至第3代,收集细胞,用流式细胞仪检测细胞表面抗原的表达水平发现CD34、CD45均<5%,呈阴性;CD29、CD73、CD90、 CD105均>95%,呈阳性。由此可见,使用本发明培养基以及培养方法培养的脂肪干细胞能保持良好的干细胞特性。
上述说明示出并描述了发明的若干优选实施例,但如前所述,应当理解发明并非局限于本文所披露的形式,不应看作是对其他实施例的排除,而可用于各种其他组合、修改和环境,并能够在本文所述发明构想范围内,通过上述教导或相关领域的技术或知识进行改动。而本领域人员所进行的改动和变化不脱离发明的精神和范围,则都应在发明所附权利要求的保护范围内。
Claims (5)
1.一种人脂肪干细胞无血清培养基,其特征在于,包括DMEM/F12基础培养基和添加成分,其中主要添加成分为:人血清白蛋白(HSA)、B27添加剂或类似物、碱性成纤维生长因子(bFGF)、酸性成纤维生长因子(aFGF)、血小板源生长因子(PDGF)、表皮生长因子(EGF)、***(IGF)、肝素(HPS)、纤粘连蛋白、抗坏血酸磷酸酯镁盐(Vc-Mg)、N-乙酰半胱氨酸(NAC)、庆大霉素和两性霉素(Gent-AMP)。
2.根据权要求1所述的人脂肪干细胞无血清培养基,其特征在于,所述DMEM/F12基础培养基中DMEM培养基与F12培养基的质量比为1:2。
3.根据权利要求1或2所述的人脂肪干细胞无血清培养基,其特征在于,所述添加成分在DMEM/F12基础培养基中的含量为:
B27添加剂或类似物(B27)(100×):1×;
HSA:2-50mg/ml;
IGF:1-100ng/ml
bFGF:2-20ng/ml;
aFGF:2-20ng/ml;
PDGF:2-20ng/ml;
EGF:2-20ng/ml;
Vc-Mg:10-100μg/ml
NAC:1-10mg/ml;
肝素(HPS):1-10mg/ml;
纤粘连蛋白(FN):10-100ug/ml;
庆大霉素(Gent):1-20μg/ml;
两性霉素(AMP):1-5μg/ml。
4.权利要求1-3任一项所述的人脂肪干细胞无血清培养基的制备方法,其特征在于,在无菌环境下下,取DMEM/F12基础培养基,依次加入HSA、B27、bFGF、aFGF、PDGF、EGF、HPS、FN、Vc-Mg、NAC、Gent-AMP,混合均匀,得到人脂肪干细胞无血清培养基。
5.权利要求1-4任一项所述的人脂肪干细胞无血清培养基在培养人脂肪干细胞中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010330554.3A CN111471651A (zh) | 2020-04-24 | 2020-04-24 | 一种人脂肪干细胞无血清培养基及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010330554.3A CN111471651A (zh) | 2020-04-24 | 2020-04-24 | 一种人脂肪干细胞无血清培养基及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111471651A true CN111471651A (zh) | 2020-07-31 |
Family
ID=71761762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010330554.3A Pending CN111471651A (zh) | 2020-04-24 | 2020-04-24 | 一种人脂肪干细胞无血清培养基及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111471651A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113801836A (zh) * | 2020-06-16 | 2021-12-17 | 台湾粒线体应用技术股份有限公司 | 提升线粒体功能的培养方法及其使用的组合物 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006134951A1 (ja) * | 2005-06-13 | 2006-12-21 | Biomaster, Inc. | 脂肪由来幹細胞の長期培養増殖法 |
US20120220034A1 (en) * | 2009-10-31 | 2012-08-30 | New World Laboratories Inc. | Methods for Reprogramming Cells and Uses Thereof |
CN102703385A (zh) * | 2012-06-26 | 2012-10-03 | 亚太干细胞科研中心有限公司 | 一种间充质干细胞培养液 |
CN103243071A (zh) * | 2013-05-09 | 2013-08-14 | 陈云燕 | 一种临床级人间充质干细胞无血清完全培养基 |
CN104877962A (zh) * | 2015-04-15 | 2015-09-02 | 广州赛莱拉干细胞科技股份有限公司 | 一种无血清的脂肪干细胞培养基及其制备方法 |
CN106754675A (zh) * | 2016-12-21 | 2017-05-31 | 广东科玮生物技术股份有限公司 | 一种脂肪干细胞无血清培养基及其制备方法和用途 |
-
2020
- 2020-04-24 CN CN202010330554.3A patent/CN111471651A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006134951A1 (ja) * | 2005-06-13 | 2006-12-21 | Biomaster, Inc. | 脂肪由来幹細胞の長期培養増殖法 |
US20120220034A1 (en) * | 2009-10-31 | 2012-08-30 | New World Laboratories Inc. | Methods for Reprogramming Cells and Uses Thereof |
CN102703385A (zh) * | 2012-06-26 | 2012-10-03 | 亚太干细胞科研中心有限公司 | 一种间充质干细胞培养液 |
CN103243071A (zh) * | 2013-05-09 | 2013-08-14 | 陈云燕 | 一种临床级人间充质干细胞无血清完全培养基 |
CN104877962A (zh) * | 2015-04-15 | 2015-09-02 | 广州赛莱拉干细胞科技股份有限公司 | 一种无血清的脂肪干细胞培养基及其制备方法 |
CN106754675A (zh) * | 2016-12-21 | 2017-05-31 | 广东科玮生物技术股份有限公司 | 一种脂肪干细胞无血清培养基及其制备方法和用途 |
Non-Patent Citations (2)
Title |
---|
周六杰等: "生长因子分步诱导法在大鼠脂肪干细胞向神经细胞分化中的应用观察", 《山东医药》, no. 47, pages 25 - 28 * |
汪谦主编: "《现代医学实验方法》", vol. 1998, 人民卫生出版社, pages: 1 - 3 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113801836A (zh) * | 2020-06-16 | 2021-12-17 | 台湾粒线体应用技术股份有限公司 | 提升线粒体功能的培养方法及其使用的组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2901105C (en) | Stem cell growth media and methods of making and using same | |
KR101264940B1 (ko) | 배아 줄기 세포용 배지 및 이의 배양물 | |
EP3828263B1 (en) | Method and kit for preparing clinical-grade mesenchymal stem cells derived from human induced pluripotent stem cells | |
EP2752484A1 (en) | Method for preparing a basic culture medium for mesenchymal stem cells, basic culture medium for mesenchymal stem cells, and cell therapeutic agent cultured and differentiated using same | |
EP3074505B1 (en) | Serum-free medium | |
CN102827804A (zh) | 适用于Vero细胞微载体悬浮放大培养的培养基及方法 | |
CN110331130B (zh) | 一种间充质干细胞无血清培养基及其用途 | |
WO1999063058A1 (fr) | Milieu de culture de cellules animales et procede de production de proteines en utilisant ce milieu | |
KR102292132B1 (ko) | 무혈청 배지 조성물 | |
CN111440764B (zh) | 间充质干细胞的无血清培养基及间充质干细胞的临床级规模化培养方法 | |
JP2023521273A (ja) | ウシ前駆細胞を培養する為の無血清培地 | |
CN111235101B (zh) | 一种人脐带间充质干细胞培养基及人脐带间充质干细胞的培养方法 | |
CN116194572A (zh) | 用于产生间充质干细胞的培养基和方法 | |
CN111471651A (zh) | 一种人脂肪干细胞无血清培养基及其制备方法 | |
CN112391340A (zh) | 一种间充质干细胞培养基 | |
KR101753557B1 (ko) | 줄기세포 증식 향상 배지 조성물 및 줄기세포의 배양방법 | |
US20230002729A1 (en) | Cell culture medium composition | |
CN112342187A (zh) | 一种软骨细胞培养基及其制备方法 | |
CN112779220A (zh) | 一种用于神经干细胞扩增的培养基 | |
CN111996164A (zh) | 一种间充质干细胞的无血清抗衰老培养基 | |
CN102433298A (zh) | 小鼠脂肪干细胞培养液 | |
CN116004521B (zh) | 一种用于鸡肌源性干细胞体外增殖的培养基及制备方法和应用 | |
CN110607272A (zh) | 一种哺乳动物细胞培养液的添加剂及细胞培养液 | |
CN112725269B (zh) | 一种无血清培养基的添加剂及其制备方法和应用 | |
US20110143432A1 (en) | Use of extract of selenium-enriched yeast (se-ye) in mammalian cell culture media formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200731 |